A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer

Trial Profile

A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2015

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Mar 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 06 May 2014 According to ClinicalTrials,gov record, status changed from not yet recruiting to recruiting.
    • 22 Jul 2013 Planned initiation date changed from 1 Mar 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top